Company: ZVRA
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001437749-25-016523
Chunk: 98

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 98
---
 remaining lease term and weighted average discount rate):

       March 31,    December 31,  
   2025    2024  
 Finance Leases         
 Property and equipment, at cost  $1,031  $1,031 
 Less: accumulated depreciation and amortization   (1,024)  (1,023)
 Property and equipment, net  $7  $8 
         
 Operating Leases         
 Operating lease right-of-use assets  $1,636  $657 
 Total operating lease right-of-use assets  $1,636  $657 
         
 Current portion of operating lease liabilities  $589  $420 
 Operating lease liabilities, less current portion   1,158   372 
 Total operating lease liabilities  $1,747  $792 
         
 Weighted Average Remaining Lease Term         
 Operating leases (in years)   3   3 
         
 Weighted Average Discount Rate         
 Operating leases   12.3%  9.9%

   Maturities of lease liabilities were as follows (in thousands):

       Operating  
 Year Ending December 31,   Leases  
 2025 (excluding the three months ended March 31, 2025)  $595 
 2026   607 
 2027   545 
 2028   365 
 2029   40 
 Thereafter   — 
 Total lease payments   2,152 
 Less: future interest expense   (405)
 Lease liabilities  $1,747 

       22

    L.  Goodwill & Intangible Assets

   The Company's goodwill balance was $4.7 million as of  March 31, 2025, and  December 31, 2024. 
    
   As of  March 31, 2025, and  December 31, 2024, non-amortizable intangible assets of $2.0 million related to in-process research and development associated with the Merger.

      As of  March 31, 2025, and  December 31, 2024, the Company had a definite-lived intangible asset, net related to the acquisition of OLPRUVA as a result of the Merger of $60.0 million and $61.3 million, respectively